PDEXHealthcare · Medical Instruments & SuppliesPDEX Stock Forecast: Pro-Dex, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Pro-Dex, Inc. hold a median 12-month price target of $70 — +10.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
PDEX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Pro-Dex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Pro-Dex, Inc. — and when they’d sell — is the membership.
PDEX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PDEX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 May 2026 | Ascendiant Capital | Maintains | Buy | $56 → $70 |
| 27 May 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Feb 2025 | Ascendiant Capital | Maintains | Buy | — |
| 11 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 9 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 4 Jan 2017 | Ascendiant Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PDEX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Pro-Dex, Inc. (PDEX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 16.1×
- Price / sales
- 2.5×
- Price / book
- 4.1×
- EV / EBITDA
- 16.2×
Cheaper than 45% of US stocks
Cheaper than 47% of US stocks
Cheaper than 25% of US stocks
Cheaper than 21% of US stocks
- Revenue growth (YoY)
- 14.6%
- Earnings growth (YoY)
- 20.2%
- Gross margin
- 30.7%
- Operating margin
- 15.5%
- Net margin
- 16.1%
Higher than 64% of US stocks
Higher than 61% of US stocks
Higher than 37% of US stocks
Higher than 75% of US stocks
Higher than 79% of US stocks
- Return on equity
- 29.8%
- Return on assets
- 9.7%
- Dividend yield
- —
Higher than 88% of US stocks
Higher than 92% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PDEX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PDEX appears on the weeks it earns a place.
Frequently asked questions about PDEX stock
What is the PDEX stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Pro-Dex, Inc. have a median 12-month price target of $70, with estimates ranging from $70 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PDEX stock a buy right now?
Of the 1 analysts covering Pro-Dex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pro-Dex, Inc. 81 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PDEX?
As at 1 Aug 2026, Pro-Dex, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
Will PDEX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +10.0% from the last close, and Ticker Nerd's factor model ranks Pro-Dex, Inc. 81 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PDEX stock forecast for 2030?
No analyst covering Pro-Dex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDEX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $70 over the next 12 months.
How has PDEX stock performed over the past year?
Pro-Dex, Inc. returned +34.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pro-Dex, Inc. do?
Pro-Dex Inc. is a manufacturer known for precision machined products, offering a range of technology solutions primarily to the medical and dental industries.
About Pro-Dex, Inc.
Pro-Dex Inc. is a manufacturer known for precision machined products, offering a range of technology solutions primarily to the medical and dental industries. The company's core business involves the design and production of intricate, high-precision electric and pneumatic motors used in surgical and dental applications. Pro-Dex excels in creating customized solutions that meet the specific needs of its clients, which includes top-tier medical device companies. Additionally, Pro-Dex provides design, assembly, and manufacturing services for its partners, demonstrating its versatility and capability in the engineering and manufacturing landscape. The firm is headquartered in Irvine, California and is committed to quality and innovation in mechanical offerings. Pro-Dex's impact stretches beyond healthcare, as it also serves sectors needing precision machining, like industrial automation. This agility in addressing diverse industry demands underscores Pro-Dex's significant role in the niche segment of manufacturing precision-engineered products, strengthening its reputation as a reliable and innovative partner in its industry.
CEO Mr. Richard Lee Van Kirk Jr. · 179 employees · United States · https://www.pro-dex.com